Health-Related quality of life, treatment satisfaction, adherence and persistence in β -thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: Results from the EPIC clinical trial

Anemia

Volumn 2012, Issue , 2012, Pages

  Porter, John ^a   Bowden, Donald K ^b   Economou, Marina ^c   Troncy, Jacques ^d   Ganser, Arnold ^e   Habr, Dany ^f   Martin, Nicolas ^f   Gater, Adam ^g   Rofail, Diana ^g   Abetz Webb, Linda ^g   Lau, Helen ^f   Cappellini, Maria Domenica ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MONASH MEDICAL CENTRE   (Australia)

^c Aristotle University of Thessaloniki   (Greece)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f NOVARTIS PHARMA AG   (Switzerland)

^g ADELPHI REAL WORLD   (United Kingdom)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873830965     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2012/297641     Document Type: Article

References (42)

1. Delea T. E., Edelsberg J., Sofrygin O., Thomas S. K., Baladi J. F., Phatak P. D., Coates T. D., Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007 47 10 1919 1929 2-s2.0-34548708556 10.1111/j.1537-2995.2007.01416.x (Pubitemid 47438560)
2. Gabutti V., Piga A., Results of long-term iron-chelating therapy. Acta Haematologica 1996 95 1 26 36 2-s2.0-0030048681 (Pubitemid 26071428)
3. Payne K. A., Desrosiers M. P., Caro J. J., Baladi J. F., Lordan N., Proskorovsky I., Ishak K., Rofail D., Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007 47 10 1820 1829 2-s2.0-34548721000 10.1111/j.1537-2995.2007.01398.x (Pubitemid 47438548)
4. Payne K. A., Rofail D., Baladi J. F., Viala M., Abetz L., Desrosiers M. P., Lordan N., Ishak K., Proskorovsky I., Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy 2008 25 8 725 742 2-s2.0-58749094452 10.1007/s12325-008-0085-z
5. Alymara V., Bourantas D., Chaidos A., Bouranta P., Gouva M., Vassou A., Tzouvara E., Bourantas K. L., Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Hematology Journal 2004 5 6 475 479 2-s2.0-11044238013 10.1038/sj.thj.6200550 (Pubitemid 40045280)
6. Giardina P. J., Grady R. W., Chelation therapy in β -thalassemia: an optimistic update. Seminars in Hematology 2001 38 4 360 366 2-s2.0-0034783438 (Pubitemid 32995605)
7. Rebulla P., The Cooleycare Cooperative Group, Transfusion reactions in thalassemia. A survey from the Cooleycare Programme. Haematologica 1990 75 5 122 127 2-s2.0-0025107059 (Pubitemid 20359678)
8. Abetz L., Baladi J. F., Jones P., Rofail D., The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes 2006 4, article 73 2-s2.0-33750440169 10.1186/1477-7525-4-73 (Pubitemid 44649664)
9. Delea T. E., Hagiwara M., Thomas S. K., Baladi J. F., Phatak P. D., Coates T. D., Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology 2008 83 4 263 270 2-s2.0-41449084967 10.1002/ajh.21049 (Pubitemid 351458002)
10. Evangeli M., Mughal K., Porter J. B., Which psychosocial factors are related to chelation adherence in thalassemia a systematic review. Hemoglobin 2010 34 3 305 321 2-s2.0-77953239810 10.3109/03630269.2010.485080
11. Kwiatkowski J. L., Real-world use of iron chelators. ASH Education Book 2011 2011 451 458
12. Cappellini M. D., Porter J., El-Beshlawy A., Li C. K., Seymour J. F., Elalfy M., Gattermann N., Giraudier S., Lee J. W., Chan L. L., Lin K. H., Rose C., Taher A., Thein S. L., Viprakasit V., Habr D., Domokos G., Roubert B., Kattamis A., Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias. Haematologica 2010 95 4 557 566 2-s2.0-77950682176 10.3324/haematol.2009.014696
13. Gattermann N., Finelli C., Porta M. D., Fenaux P., Ganser A., Guerci-Bresler A., Schmid M., Taylor K., Vassilieff D., Habr D., Domokos G., Roubert B., Rose C., Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leukemia Research 2010 34 9 1143 1150 2-s2.0-77955268192 10.1016/j.leukres.2010.03.009
14. Cappellini M. D., Bejaoui M., Agaoglu L., Porter J., Coates T., Jeng M., Lai M. E., Mangiagli A., Strauss G., Girot R., Watman N., Ferster A., Loggetto S., Abish S., Cario H., Zoumbos N., Vichinsky E., Opitz H., Ressayre-Djaffer C., Abetz L., Rofail D., Baladi J. F., Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β -thalassemia. Clinical Therapeutics 2007 29 5 909 917 2-s2.0-34547824328 10.1016/j.clinthera.2007.05.007 (Pubitemid 47241173)
15. Vichinsky E., Pakbaz Z., Onyekwere O., Porter J., Swerdlow P., Coates T., Lane P., Files B., Mueller B. U., Coïc L., Forni G. L., Fischer R., Marks P., Rofail D., Abetz L., Baladi J. F., Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematologica 2008 119 3 133 141 2-s2.0-46049087344 10.1159/000125550 (Pubitemid 351896547)
16. Ratip S., Skuse D., Porter J., Wonke B., Yardumian A., Modell B., Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis. Archives of Disease in Childhood 1995 72 5 408 412 2-s2.0-0029048027
17. Jansen A. J. G., Essink-Bot M. L., Beckers E. A. M., Hop W. C. J., Schipperus M. R., Van Rhenen D. J., Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. British Journal of Haematology 2003 121 2 270 274 2-s2.0-0037541576 10.1046/j.1365-2141.2003.04272.x (Pubitemid 36560593)
18. Sobota A., Yamashita R., Xu Y., Trachtenberg F., Kohlbry P., Kleinert D. A., Giardina P. J., Kwiatkowski J. L., Foote D., Thayalasuthan V., Porter J. B., Thompson A. A., Schilling L., Quinn C. T., Neufeld E. J., Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology 2011 86 1 92 95 2-s2.0-78650317859 10.1002/ajh.21896
19. Mednick L., Yu S., Trachtenberg F., Xu Y., Kleinert D. A., Giardina P. J., Kwiatkowski J. L., Foote D., Thayalasuthan V., Porter J. B., Thompson A. A., Schilling L., Quinn C. T., Neufeld E. J., Yamashita R., Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort. American Journal of Hematology 2010 85 10 802 805 2-s2.0-77957688789 10.1002/ajh.21826
20. Scalone L., Mantovani L. G., Krol M., Rofail D., Ravera S., Bisconte M. G., Borgna-Pignatti C., Borsellino Z., Cianciulli P., Gallisai D., Prossomariti L., Stefàno I., Cappellini M. D., Costs, quality of life, treatment satisfaction and compliance in patients with β -thalassemia major undergoing iron chelation therapy: the ITHACA study. Current Medical Research and Opinion 2008 24 7 1905 1917 2-s2.0-47949125257 10.1185/03007990802160834
21. Ware J. E., Sherbourne C. D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 6 473 483 2-s2.0-0026877917
22. Ware J. E., Kosinski M., Dewey J. E., How to Score version two of the SF-36 Health Survey 2000 Lincoln, RI, USA QualityMetric
23. Ware J. E., Kosinski M., Bjorner J. B., User's Manual for the SF-36v2 Health Survey 2007 2nd Lincoln, RI, USA QualityMetric
24. Rofail D., Abetz L., Viala M., Gait C., Baladi J. F., Payne K., Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value in Health 2009 12 1 109 117 2-s2.0-58849157398 10.1111/j.1524-4733.2008.00390.x
25. Rofail D., Viala M., Gater A., Abetz-Webb L., Baladi J. F., Cappellini M. D., An instrument assessing satisfaction with iron chelation therapy: psychometric testing from an open-label clinical trial. Advances in Therapy 2010 27 8 533 546 2-s2.0-77956226703 10.1007/s12325-010-0049-y
26. Jenkinson C., Stewart-Brown S., Petersen S., Assessment and evaluation of the SF36 Version II. Health Services Research Unit, University of Oxford, 2006, http://www hsru ox ac uk/sf36v2 htm
27. Guyatt G. H., Osoba D., Wu A. W., Wyrwich K. W., Norman G. R., Aaronson N., Barofsky I., Berzon R., Bonomi A., Bullinger M., Cappelleri J. C., Cella D., Fairclough D., Ferrans C. E., Frost M., Hays R. D., Marquis P., Moinpour C. M., Moynihan T., Patrick D., Revicki D., Rummans T., Scott C., Sloan J. A., Sprangers M., Symonds T., Varricchio C., Wong G., Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings 2002 77 4 371 383 2-s2.0-0036195669 (Pubitemid 34260746)
28. Sloan J. A., Cella D., Hays R. D., Clinical significance of patient-reported questionnaire data: another step toward consensus. Journal of Clinical Epidemiology 2005 58 12 1217 1219 2-s2.0-27744532631 10.1016/j.jclinepi.2005.07.009 (Pubitemid 41608536)
29. Wyrwich K. W., Tierney W. M., Wolinsky F. D., Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology 1999 52 9 861 873 2-s2.0-0033199526 10.1016/S0895-4356(99)00071-2 (Pubitemid 29385600)
30. Pinchon D. J., Stanworth S. J., Dorée C., Brunskill S., Norfolk D. R., Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. American Journal of Hematology 2009 84 10 671 677 2-s2.0-70349502130 10.1002/ajh.21503
31. Haines D., Carson S., Green S., Martin M., Coates T. D., Vega O. O., Phenomenon of pain in thalassemia: a prospective analysis by the thalassemia clinical research network (TCRN). Blood (ASH Annual Meeting Abstracts) 2010 116, article 253
32. Malcovati L., Della Porta M. G., Pascutto C., Invernizzi R., Boni M., Travaglino E., Passamonti F., Arcaini L., Maffioli M., Bernasconi P., Lazzarino M., Cazzola M., Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology 2005 23 30 7594 7603 2-s2.0-32144431895 10.1200/JCO.2005.01.7038 (Pubitemid 46291823)
33. Malcovati L., Germing U., Kuendgen A., Della Porta M. G., Pascutto C., Invernizzi R., Giagounidis A., Hildebrandt B., Bernasconi P., Knipp S., Strupp C., Lazzarino M., Aul C., Cazzola M., Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology 2007 25 23 3503 3510 2-s2.0-34548219420 10.1200/JCO.2006.08.5696 (Pubitemid 47315575)
34. Ma X., Does M., Raza A., Mayne S. T., Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007 109 8 1536 1542 2-s2.0-34247172535 10.1002/cncr.22570 (Pubitemid 46595689)
35. Pearson H. A., Cohen A. R., Giardina P. J. V., Kazazian H. H., The changing profile of homozygous β -thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics 1996 97 3 352 356 2-s2.0-0029866325 (Pubitemid 26076260)
36. Telfer P., Update on survival in thalassemia major. Hemoglobin 2009 33 1 S76 S80 2-s2.0-73949117408 10.3109/03630260903347336
37. Yamashita R., Xu Y., Trachtenberg F., Kohlbry P., Kleinert D. A., Giardina P., Changes in health status and quality of life in adults with thalassemia: year 1 report of the thalassemia longitudinal cohort study. Blood (ASH Annual Meeting Abstracts) 2010 116, article 1533
38. Malcovati L., Della Porta M. G., Cazzola M., Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006 91 12 1588 1590 2-s2.0-33845935490 (Pubitemid 46032954)
39. Fey M. F., Dreyling M., Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010 21 supplement 5 v158 v161 2-s2.0-77954317788 10.1093/annonc/mdq179
40. Kwiatkowski J. L., Kim H. Y., Thompson A. A., Quinn C. T., Mueller B. U., Odame I., Chelation use and iron burden in North American and British thalassemia patients: a report from the thalassemia longitudinal cohort. Blood 2012 119 12 2746 2753
41. Trachtenberg F., Vichinsky E., Haines D., Pakbaz Z., Mednick L., Sobota A., Kwiatkowski J., Thompson A. A., Porter J., Coates T., Giardina P. J., Olivieri N., Yamashita R., Neufeld E. J., Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology 2011 86 5 433 436 2-s2.0-79955151475 10.1002/ajh.21993
42. Jenkinson C., Stewart-Brown S Petersen S., Paice C., Assessment of the SF-36 version 2 in the United Kingdom. Journal of Epidemiology and Community Health 1999 53 1 46 50 10.1136/jech.53.1.46 (Pubitemid 29012351)